Riskkapitalbolaget EQT har tagit kontroll över svenska CDMO-företaget Recipharm.

EQT IX har, genom Roar BidCo, offentliggjort ett offentligt uppköpserbjudande om 220 kronor kontant per aktie till aktieägarna i Recipharm, motsvarande 1 427 010 kronor kontant per konvertibel med ett nominellt belopp om 1 000 000 kronor.

Det framgår av ett pressmeddelande. I erbjudandet ingår också 1.427.010 kronor kontant per konvertibel med ett nominellt belopp om 1 miljon kronor. Lars Backsell, styrelseordförande i Recipharm, och Swedish private equity firm EQT declared its offer for pharmaceutical development and manufacturing company Recipharm unconditional. EQT IX, through Roar BidCo, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85bn), but raised the bid to SEK24.93 billion last month.

EQT intends to acquire Recipharm. AK&M. 15 December 2020 12:32. 90. 1.

Swedish private equity firm EQT declared its offer for pharmaceutical development and manufacturing company Recipharm unconditional. EQT IX, through Roar BidCo, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85bn), but raised the bid to SEK24.93 billion last month.

EQT IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond. 14 December 2020. #Press Release.

STOCKHOLM--Swedish private-equity firm EQT AB on Monday declared its offer for pharmaceutical development and manufacturing company Recipharm AB unconditional. EQT IX, through Roar BidCo AB, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85 billion), but raised the bid to SEK24.93 billion last month.

EQT : Roar BidCo EQT : Closes Offer Period for Recipharm Acquisition With Over 95% Stake: MT. More news: Financials . Sales 2020: 11 124 M 1 302 M 1 302 M: Net Private Equity EQT Offers To Acquire Swedish Pharma Recipharm For $2.1B

Benzinga.
Fastlandsklimat temperatur

Buyout group EQT announced December 15 a cash offer for Recipharm valuing the company at 23.6 billion Swedish crowns ($2.80 billion), as it was informed by EQT. Som en mycket aktiv investerare inom den globala hälsovårdssektorn, är EQT väl positionerade att hjälpa Recipharm att framtidssäkra verksamheten och accelerera sin tillväxt. Vi är övertygade om att vi kan tillföra betydande värde, både i form av expertis och kapital, säger Erika Henriksson, Partner på EQT Partners och investeringsrådgivare åt EQT IX, i en skriftlig kommentar. In December 2020, EQT IX, through Roar BidCo AB, announced a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB and SEK 1,427,010 in cash per Convertible Bond. The class B shares in Recipharm are listed on Nasdaq Stockholm, Mid Cap. Riskkapitalbolaget EQT höjer budet på Recipharm från 220 till 232 kronor per aktie och konvertibelägarna erbjuds 1 504 295 kronor per Konvertibel. Detta är en låst artikel Registrera dig för Mitt DJ Premiumkonto och få tillgång direkt till introduktionspriset 69 kr/mån inkl.

Bolagets båda grundare, ordföranden Lars Backsell och vd:n Thomas Eldered, deltar i erbjudandet.
Omval sverige

12 Feb 2021 The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of Recipharm of Sweden by EQT

In December 2020, EQT IX, through Roar BidCo AB, announced a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB and SEK 1,427,010 in cash per Convertible Bond. The class B shares in Recipharm are listed on Nasdaq Stockholm, Mid Cap. EQT wants to support Recipharm’s continued development, which will require significant and long-term investments.” EQT offers to acquire Swedish CDMO Recipharm for $2.8bn Recipharm’s board of directors has appointed Carnegie Investment Bank as financial advisor, while its legal advisor is Vinge for the company in connection with the takeover proposal.

Svensk konsulat

STOCKHOLM (Reuters) -Buyout group EQT on Monday announced a cash offer for Swedish contract pharmaceutical maker Recipharm, valuing the company at 23.6 billion Swedish crowns ($2.80 billion).

EQT IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond EQT said it had secured ownership of around 25.7 per cent of Recipharm shares and 74.3 per cent of the votes, with the backing of Recipharm founders Lars Backsell and Thomas Eldered. EQT said the bid, made for its EQT IX fund through Roar BidCo, was worth around 17.9 billion crowns for the shares and convertible bonds it did not control. Roar BidCo does not hold any other financial instruments that give financial exposure to Recipharm's shares and has not acquired any such shares or financial instruments outside the Revised Offer. Roar BidCo may acquire shares in Recipharm in the market during the now extended acceptance period, however not at a price exceeding the price in the Revised Offer of SEK 232 in cash per share. 2020-12-14 2020-12-14 EQT IX har, genom Roar BidCo, offentliggjort ett offentligt uppköpserbjudande om 220 kronor kontant per aktie till aktieägarna i Recipharm, motsvarande 1 427 010 kronor kontant per konvertibel med ett nominellt belopp om 1 000 000 kronor.

2020-12-14 · EQT said it was bidding 220 crowns per Recipharm share, a 22.9% premium to Recipharm's closing price on Friday. EQT said it had secured ownership of around 25.7% of Recipharm shares and 74.3% of

2020-12-14 Buyout group EQT on Monday announced a cash offer for Swedish contract pharmaceutical maker Recipharm, valuing the company at 23.6 billion Swedish crowns ($2.80 billion). Recipharm employs more than 9,000 employees in Europe, the US and India. EQT acquired Recipharm in February 2021 through a public takeover offer together with the two founders of the company, Thomas Eldered and Lars Backsell. To Recipharm. Market Trends and Drivers 2020-12-14 Swedish private equity firm EQT declared its offer for pharmaceutical development and manufacturing company Recipharm unconditional. EQT IX, through Roar BidCo, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85bn), but raised the bid to SEK24.93 billion last month.

No acquisitions were made at a price that exceeds the consideration in the Revised Offer. On 11 February 2021, the European Commission announced that it has decided under Article 6(1)(b) of the EU Merger Regulation to approve the acquisition of joint control of Recipharm by EQT… EQT's bid also follows news from Recipharm that a molecule it's developing, Erdosteine, appeared to help Covid patients recover after they were discharged from hospital. The company, whose biggest shareholder is the Swedish state with a roughly 16 per cent stake, has seen its share price gain about 36 per cent this year. Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to company's press release. The transaction will be routed through Roar BidCo AB, a limited liability company established on Nov. 10, 2020, wholly-owned by EQT. Why Does It Matter: The purchased consideration is fixed at 220 SEK per share in cash, a 23% premium on 2020-12-14 Stockholm-based EQT has already secured ownership of about 25.7% of the shares and 74.3% of the votes in Recipharm through its chairman, Lars Backsell, and Thomas Eldered, its chief executive.